Yunong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunong Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Lijuan Xing
Precision Laboratory Panjin Central Hospital Panjin P.R. China
1 shared publication - Lin Zhao
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, People’s Republic of China
1 shared publication - Mingyi Ju
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
1 shared publication - Minjie Wei
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
1 shared publication - Yuxi Miao
Department of Pharmacology, School of Pharmacy China Medical University Shenyang P.R. China
1 shared publication
Latest Publications
- 17 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23236
Advancement of anti‐LAG ‐3 in cancer therapy
Immune checkpoint inhibitors have effectively transformed the treatment of many cancers, particularly those highly devastating malignancies. With their widespread popularity, the drawbacks of immune checkpoint inhibitors are also recognized, such as drug resistance and immune‐related systematic side effects. Thus, it never stops investigating novel immune checkpoint inhibitors. Lymphocyte Activation Gene‐3 (LAG‐3) is a well‐established co‐inhibitory receptor that performs negative regulation on immune responses. Recently, a novel FDA‐approved LAG‐3 blocking agent, together with nivolumab as a new combinational immunotherapy for metastatic melanoma, brought LAG‐3 back into focus. Clinical data suggests that anti‐LAG‐3 agents can amplify the therapeutic response of other immune checkpoint inhibitors with manageable side effects. In this review, we elucidate the intercellular and intracellular mechanisms of LAG‐3, clarify the current understanding of LAG‐3 in the tumor microenvironment, identify present LAG‐3‐associated therapeutic agents, discuss current LAG‐3‐involving clinical trials, and eventually address future prospects for LAG‐3 inhibitors.
- 17 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23236
Advancement of anti‐LAG ‐3 in cancer therapy
Immune checkpoint inhibitors have effectively transformed the treatment of many cancers, particularly those highly devastating malignancies. With their widespread popularity, the drawbacks of immune checkpoint inhibitors are also recognized, such as drug resistance and immune‐related systematic side effects. Thus, it never stops investigating novel immune checkpoint inhibitors. Lymphocyte Activation Gene‐3 (LAG‐3) is a well‐established co‐inhibitory receptor that performs negative regulation on immune responses. Recently, a novel FDA‐approved LAG‐3 blocking agent, together with nivolumab as a new combinational immunotherapy for metastatic melanoma, brought LAG‐3 back into focus. Clinical data suggests that anti‐LAG‐3 agents can amplify the therapeutic response of other immune checkpoint inhibitors with manageable side effects. In this review, we elucidate the intercellular and intracellular mechanisms of LAG‐3, clarify the current understanding of LAG‐3 in the tumor microenvironment, identify present LAG‐3‐associated therapeutic agents, discuss current LAG‐3‐involving clinical trials, and eventually address future prospects for LAG‐3 inhibitors.